Form 4: IN8BIO Executive Lawrence Lamb Granted Stock Options

Lawrence Lamb, EVP and CSO of IN8BIO, Inc., was granted employee stock options on December 19, 2024.

Summary

• Lawrence Lamb, the EVP and CSO of IN8BIO, Inc., filed a Form 4 on December 23, 2024.
• The filing reports a transaction that occurred on December 19, 2024, where Lamb was granted employee stock options.
• Lamb received options to purchase 286,899 shares of IN8BIO's common stock at an exercise price of $0.24 per share.
• The options vest on December 19, 2025, contingent upon Lamb's continued service to the company.
• Following the transaction, Lamb directly owns options for 286,899 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive's ability to contribute to the company's success. However, it's not a major event that would drastically alter investor sentiment.

Positives

• The granting of stock options to a key executive like Lawrence Lamb can be seen as a positive incentive for him to remain with the company and contribute to its success.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Granting stock options is a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This aligns with standard compensation packages offered to key personnel in similar companies.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) have used similar stock option plans to incentivize key employees.
• The vesting schedule of one year is relatively standard, aligning with industry norms for executive retention.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the executive.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates